Zyprexa On More Level Playing Field After Diabetes Class Label Changes, Lilly Says

Physicians will be more inclined to prescribe atypical antipsychotics based on efficacy rather than side effects now that "virtually" all NDA holders have revised labeling, Lilly says. Pfizer (Geodon) remains the lone holdout.